Analyst Initiates Buy on Medline, Citing Attractive 2027 EBITDA Valuation, International Expansion, and Limited Impact from FDA Warning Letter

TIPRANKS06-04

William Blair analyst Brandon Vazquez has maintained their bullish stance on MDLN stock, giving a Buy rating yesterday. Brandon Vazquez has given h...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment